ORPHA:89938
Bartter syndrome type 4
Also known as: Bartter syndrome type IV · Bartter syndrome with sensorineural deafness · Bartter syndrome with sensorineural hearing loss
Publications
104
53.3th percentile
Trials
0
Interventional, condition-specific
Researchers
600
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Clinical definition (Orphanet)
A form of Bartter syndrome characterized by maternal polyhydramnios, premature delivery, salt loss, polyuria and sensorineural deafness, associated with hypokalemic and hypochloremic alkalosis, increased levels of plasma renin and aldosterone, and low to normal blood pressure. Urinary calcium excretion rates are variable, and nephrocalcinosis is typically absent.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019524
- UMLS:C3838860
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
104 matched papers (50 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
104
104 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
104 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
50 in the last 10 years · high confidence · 53.3th percentile (publications denominator)
Phrase hits: 104 · MeSH hits: 0
Who's working on it?
600
Distinct author names in 104 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Fahlke C7 papers · 2017
Institute of Complex Systems-Zelluläre Biophysik (ICS-4), Forschungszentrum Jülich Jülich, Germany.
Papers in Europe PMC - 02Fischer M7 papers · 2020
Institut für Neurophysiologie, Medizinische Hochschule Hannover Hannover, Germany.
Papers in Europe PMC - 03Landau D7 papers · 2010
Department of Pediatrics A, Soroka University Medical Center, Ben Gurion University of the Negev, Beer-Sheva 84101, Israel. ldaniel@bgu.ac.il
Papers in Europe PMC - 04Pusch M5 papers · 2023
Institute of Biophysics, National Research Council, 16149 Genova, Italy.
Papers in Europe PMC - 05Shalev H5 papers · 2010
Department of Pediatrics, Soroka University Medical Center, Beer-Sheva, Israel.
Papers in Europe PMC - 06Konrad M4 papers · 2022
Department of General Paediatrics, Paediatric Nephrology, University Hospital Münster, Munster, Germany.
Papers in Europe PMC - 07Picollo A4 papers · 2019
Dulbecco Telethon Laboratory, Istituto di Biofisica, Consiglio Nazionale delle Ricerche, Genova, Italy; and giovanni.zifarelli@dpag.ox.ac.uk apicollo@dti.telethon.it.
Papers in Europe PMC - 08Riazuddin S4 papers · 2024
Section on Human Genetics, Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, NIH, Rockville, MD 20850, USA.
Papers in Europe PMC - 09Babini E3 papers · 2010Papers in Europe PMC
- 10Bockenhauer D3 papers · 2022
Department of Renal Medicine, University College London, London, UK.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
Broader category Bartter syndrome also has no matched interventional trial. See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Broader category: Bartter syndrome
0
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Parent-category matching found a broader label but no interventional trials under it. How we count trials.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Bartter syndrome type 4" OR "Bartter syndrome type IV" OR "Bartter syndrome with sensorineural deafness" OR "Bartter syndrome with sensorineural hearing loss"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Bartter syndrome type 4" OR "Bartter syndrome type IV" OR "Bartter syndrome with sensorineural deafness" OR "Bartter syndrome with sensorineural hearing loss"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"Bartter syndrome"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T03:28:24.895Z